Pharmaceutical Maneuvers: Europe's Drug Delays Amidst Trump's Price War
Recent health news highlights key events impacting the pharmaceutical sector. European drug launches face delays due to pricing pressures from former US President Donald Trump. The FDA warns of liver injury associated with Amgen's drug. Additionally, investor activism and strategic maneuvers reveal the ongoing dynamics within major pharma companies.
Pharmaceutical companies are postponing the launch of new drugs in Europe, largely in response to price standardization efforts initiated by former US President Donald Trump. This industry pause emerges amid global pricing strategies and market dynamics, leaving European patients awaiting new treatments.
The U.S. Food and Drug Administration has issued a health alert on liver damage cases tied to Amgen's autoimmune disease treatment. The alarming news points to 76 injury cases, including critical instances of vanishing bile duct syndrome, raising concerns over patient safety and ongoing drug use oversight.
In business developments, Pineal Capital Management is advocating for change at Teladoc Health. Urging cost reductions and considering a company split, Pineal Capital aims to enhance shareholder value and strategize for broader market opportunities. Such calls to action highlight the shifting landscapes within tech-driven healthcare companies.
Google News